

The Melanoma Research Alliance

POWERFUL RESEARCH. FASTER RESULTS.

The mission of the Melanoma Research Alliance (MRA) is to end suffering and death due to melanoma by collaborating with all stakeholders to accelerate powerful research, advance cures for all patients, and prevent more melanoma.

Melanoma
Research Alliance

C U R E M E L A N O M A . O R G

MRA Grant Award Mechanisms

- **Team Science Award:** multidisciplinary teams and involvement of Young Investigator. \$900k and up, over 3-years.
- **Established Investigator Award (EIA):** past their first five years of appointment with an established record of scientific productivity. \$375k over 3-years.
- **Young Investigator Award (YIA):** within five years of first faculty appointment, requiring a mentorship commitment from a senior investigator. \$255k over 3-years.
- **Pilot Award:** test potentially transformative ideas that do not require extensive preliminary data, but articulate a clear hypothesis – “high-risk, high-reward.” \$100k over 2-years.
- **Dermatology Career Development Award:** engaging early career clinical dermatologists in melanoma research (\$150k over 2-years).
- **Academic-Industry Partnerships:** Investigator-initiated research or trials for Team or EIA awards that are co-partnered with industry

By The **Numbers**: MRA's Research Investments



\$162M+

Since 2007, MRA has invested over \$162M in melanoma research

\$100k
Licensing revenue returned to MRA



475+

MRA has supported >475 research projects at 160 institutions



19

MRA has funded research in 19 countries

>\$450M
Follow-on funding



225

Unique Therapeutic Approaches Studied



61

Clinical Trials Supported by MRA




17

Approved Therapeutics




Thousands
of lives saved and patients cured

Timeline



Timeline



Advancing Discoveries, Changing Lives, Curing Melanoma (2024 – 2029)

Although MRA is seen as the non-profit leader in applying innovative models and approaches to research and has had numerous successes in advancing critical scientific and clinical questions for melanoma patients, there is still more work to be done. Three key areas MRA is focused on:

Prevention, Detection & Diagnosis

Investments in AI, machine learning, informatics and other technologies to improve prevention, detection and diagnosis

New Treatments

Develop new treatments for 50% of patients with tumors that do not respond to current treatments.

Special emphasis on patients with brain metastasis and LMD

RARE Melanomas

Acral Melanoma Global Consortium

RARE Melanoma Translational Research Accelerator & RARE Registry

Strategic investments across rare melanomas to translate research from lab bench to bedside

Rare Melanomas (acral, mucosal, uveal)

Cutaneous Melanoma of the Skin

Face/head/neck (20%)

Arm/shoulder (22%)

Hip/legs (19%)

uveal/ocular melanoma (5%)


Body/trunk (30%)

mucosal melanoma (1-2%)

-sinus cavity, oral cavity, GI tract, genital tract

acral melanoma (2-3%)



-palms, soles, nail beds



106,000 cases in the US this year


RARE Registry

- RARE is a web-based, direct to patient registry for patients with acral, mucosal, and cutaneous melanomas.
- Participants fill out a series of surveys and are also able to upload medical reports.
- Opportunity to fill out additional surveys as they are made available.



RareMelanoma.org

ALM is the most common type of melanoma in several countries in LatAm, Africa and Asia





Melanoma


Research Alliance

C U R E M E L A N O M A . O R G

Marc Hurlbert, PhD; CEO – mhurlbert@curemelanoma.org

Stephanie Kauffman; President and COO – skauffman@curemelanoma.org

Joan Levy, PhD; CSO – jlevy@curemelanoma.org



Melanoma Research Alliance
730 15th Street, NW
Fourth Floor
Washington DC, 20005

